7Baggers

Mirum Pharmaceuticals, Inc
(NASDAQ:MIRM) 

MIRM stock logo

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial ...

Founded: 2018
Full Time Employees: 67
CEO: Christopher Peetz  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
                             
      revenue:
    		                         
      product sales
    		133,010,000 127,785,000 111,585,000 99,430,000 90,302,000 77,760,000 68,917,000 69,554,000 47,725,000 32,497,000 29,098,000 27,906,000 18,780,000 10,892,000            
      license and other revenue
    		   -16,000 75,000 115,000 305,000                   
      total revenue
    		133,010,000 127,785,000 111,585,000 99,414,000 90,377,000 77,875,000 69,222,000 69,554,000 47,725,000 37,497,000 31,598,000 27,906,000 18,780,000 12,892,000            
      yoy
    		47.17% 64.09% 61.20% 42.93% 89.37% 107.68% 119.07% 149.24% 154.13% 190.85%                
      qoq
    		4.09% 14.52% 12.24% 10.00% 16.05% 12.50% -0.48% 45.74% 27.28% 18.67% 13.23% 48.59% 45.67%             
      operating expenses:
    		                         
      cost of sales
    		25,537,000 23,421,000 23,018,000 22,780,000 20,806,000 20,227,000 17,830,000 25,020,000 10,228,000 6,812,000 4,979,000 4,494,000 2,932,000 2,424,000            
      research and development
    		42,960,000 46,067,000 46,044,000 44,026,000 31,710,000 32,672,000 32,222,000 30,935,000 26,117,000 22,009,000 23,548,000 31,105,000 26,217,000 24,088,000 27,775,000 30,471,000 35,048,000 38,134,000 29,726,000 15,984,000 18,555,000 17,340,000 -26,280,000 3,000 11,589,000 
      selling, general and administrative
    		61,910,000 63,286,000 57,706,000 56,830,000 50,545,000 49,208,000 45,638,000 46,184,000 36,528,000 32,949,000 30,219,000 26,468,000 22,513,000 19,116,000            
      total operating expenses
    		130,407,000 132,774,000 126,768,000 123,636,000 103,061,000 102,107,000 95,690,000 102,139,000 72,873,000 61,770,000 58,746,000 62,067,000 51,662,000 45,628,000 48,713,000 47,824,000 48,401,000 47,613,000 36,951,000 21,716,000 23,597,000 22,032,000 -18,679,000 65,000 14,034,000 
      income from operations
    		2,603,000 -4,989,000 -15,183,000 -24,222,000 -12,684,000 -24,232,000 -26,468,000 -32,585,000 -25,148,000 -24,273,000 -27,148,000 -34,161,000 -32,882,000 -32,736,000 -45,575,000 -42,824,000 -37,401,000 -47,613,000 -36,951,000 -21,716,000 -23,597,000 -22,032,000 18,679,000 -65,000 -14,034,000 
      yoy
    		-120.52% -79.41% -42.64% -25.67% -49.56% -0.17% -2.50% -4.61% -23.52% -25.85% -40.43% -20.23% -12.08% -31.25% 23.34% 97.20% 58.50% 116.11% -297.82% 33309.23% 68.14%     
      qoq
    		-152.17% -67.14% -37.32% 90.96% -47.66% -8.45% -18.77% 29.57% 3.60% -10.59% -20.53% 3.89% 0.45% -28.17% 6.42% 14.50% -21.45% 28.85% 70.16% -7.97% 7.10% -217.95% -28836.92% -99.54%  
      operating margin %
    		1.96% -3.90% -13.61% -24.36% -14.03% -31.12% -38.24% -46.85% -52.69% -64.73% -85.92% -122.41% -175.09% -253.92% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% 
      other income:
    		                         
      interest income
    		3,251,000 3,033,000 3,023,000 3,204,000 3,469,000 3,486,000 3,633,000 3,775,000 4,061,000 3,627,000 2,272,000 2,143,000 1,352,000 69,000 65,000 72,000 80,000 149,000 168,000 237,000 405,000 749,000 -1,413,000 -2,000 468,000 
      interest expense
    		-3,606,000 -3,589,000 -3,596,000 -3,579,000 -3,586,000 -3,569,000 -3,577,000 -3,563,000 -3,574,000 -3,726,000 -4,242,000 -4,359,000 -3,971,000 -3,774,000 -3,766,000 -5,667,000 -4,776,000 -3,381,000        
      other income
    		395,000 86,000 2,108,000 231,000 -1,087,000 312,000 1,757,000 -3,061,000 1,322,000 -274,000 -811,000 -588,000 -192,000 -154,000 -17,000 -35,000 -514,000 -16,000 -83,000 -30,000 -56,000 -23,000 -13,000  9,000 
      net income before benefit from income taxes
    		2,643,000 -5,459,000 -13,648,000 -15,636,500 -13,888,000 -24,003,000 -24,655,000 -35,434,000 -23,339,000 -73,722,000 -29,929,000   -36,595,000 57,558,000 -47,099,000 -43,883,000 -50,527,000 -37,201,000 -21,509,000 -23,248,000 -21,306,000    
      (benefit from) benefit from income taxes
    		-262,000                         
      net income
    		2,905,000 -5,861,000 -14,677,000 -23,790,000 -14,235,000 -24,638,000 -25,279,000 -35,659,000 -23,588,000 -74,038,000 -30,130,000 -36,431,000 -35,706,000 -36,606,000 57,546,000 -47,108,000 -43,894,000 -50,532,000 -37,203,000 -21,506,000 -23,251,000 -21,310,000 17,253,000 -67,000 -13,557,000 
      yoy
    		-120.41% -76.21% -41.94% -33.28% -39.65% -66.72% -16.10% -2.12% -33.94% 102.26% -152.36% -22.66% -18.65% -27.56% -254.68% 119.05% 88.78% 137.13% -315.63% 31998.51% 71.51%     
      qoq
    		-149.56% -60.07% -38.31% 67.12% -42.22% -2.54% -29.11% 51.17% -68.14% 145.73% -17.30% 2.03% -2.46% -163.61% -222.16% 7.32% -13.14% 35.83% 72.99% -7.51% 9.11% -223.51% -25850.75% -99.51%  
      net income margin %
    		2.18% -4.59% -13.15% -23.93% -15.75% -31.64% -36.52% -51.27% -49.42% -197.45% -95.35% -130.55% -190.13% -283.94% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% 
      net income per share
    		0.06 -0.12 -0.3 -0.34 -0.3 -0.52 -0.54 -0.82 -0.57 -1.94 -0.8 -0.758 -1.02 -1.17 1.91 -1.55 -1.45 -1.68 -1.44 -0.86 -0.93 -0.86    
      weighted-average shares of common stock outstanding, basic
    		50,639,231        41,098,920 38,107,334   34,927,790             
      weighted-average shares of common stock outstanding, diluted
    		56,993,841        41,098,920 38,107,334   34,927,790             
      benefit from income taxes
    		 402,000 1,029,000 -576,000 347,000 635,000 624,000 225,000 249,000 316,000 201,000   11,000 12,000 9,000 11,000 5,000 2,000 -3,000 3,000 4,000    
      weighted-average shares of common stock outstanding, basic and diluted
    		 49,726,823 48,889,058  47,782,619 47,235,080 46,927,550    37,675,306   31,296,223 30,321,722 30,367,727 30,274,749 30,105,017 25,251,968 25,132,916 25,056,123 24,704,651 899,331   
      income from termination of revenue interest purchase agreement
    		         -49,076,000                
      license revenue
    		         5,000,000 2,500,000   2,000,000  5,000,000 11,000,000         
      change in fair value of derivative liability
    		           674,000   -1,149,000 1,355,000 -1,272,000 334,000        
      net income before income taxes
    		           -26,445,000 -35,693,000             
      benefit for income taxes
    		           -1,636,500 13,000             
      general and administrative
    		              10,046,250 17,353,000 13,353,000 9,479,000 7,225,000 5,732,000 5,042,000 4,692,000 -6,889,000 62,000 2,445,000 
      net income per common share, basic and diluted
    		                      -1,117.5 -140 -5,310 
      weighted-average common shares outstanding, basic and diluted
    		                       476,905,000 2,551,822,000 
                             
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
                               
        assets
      		                         
        current assets:
      		                         
        cash and cash equivalents
      		282,021,000 228,122,000 211,822,000 222,503,000 222,969,000 233,245,000 302,843,000 286,326,000 303,059,000 297,228,000 49,419,000 28,003,000 35,759,000 46,272,000 31,340,000 55,844,000 91,938,000 90,677,000 142,086,000 48,778,000 83,042,000 72,035,000 11,970,000 30,814,000 41,817,000 
        short-term investments
      		93,527,000 76,430,000 65,852,000 57,812,000 61,476,000 45,126,000   2,971,000 32,726,000 82,654,000 123,716,000 149,588,000 93,636,000 125,201,000 134,190,000 131,913,000 122,436,000 89,734,000 84,971,000 66,294,000 87,496,000 104,690,000 95,445,000 42,375,000 
        accounts receivable
      		107,132,000 106,836,000 95,852,000 78,286,000 68,530,000 60,430,000 54,999,000 67,968,000 47,834,000 35,326,000 24,661,000 23,994,000 16,337,000 7,872,000 3,267,000           
        inventory
      		24,021,000 22,941,000 22,418,000 22,403,000 21,594,000 20,438,000 21,606,000 22,312,000 22,250,000 8,509,000 6,613,000 5,565,000 6,943,000 1,580,000 1,513,000           
        prepaid expenses and other current assets
      		23,874,000 19,069,000 14,874,000 11,784,000 12,057,000 8,590,000 10,017,000 10,935,000 12,465,000 9,729,000 8,987,000 8,947,000 6,929,000 5,908,000 5,271,000 6,371,000 4,515,000 4,642,000 4,530,000 4,402,000 2,739,000 2,905,000 2,703,000 3,058,000 666,000 
        total current assets
      		530,575,000 453,398,000 410,818,000 392,788,000 386,626,000 367,829,000 389,465,000 387,541,000 388,579,000 383,518,000 172,334,000 190,225,000 215,556,000 155,268,000 166,592,000 196,805,000 228,366,000 217,755,000 236,350,000 138,151,000 152,075,000 162,436,000 119,363,000 129,317,000 84,858,000 
        restricted cash
      		480,000 480,000 425,000 425,000 425,000 250,000                    
        long-term investments
      		2,470,000 17,112,000 20,912,000 12,526,000 9,321,000 17,075,000         4,983,000       6,530,000 23,292,000 27,300,000 16,108,000 
        property and equipment
      		1,277,000 1,177,000 1,108,000 1,139,000 1,212,000 1,101,000 501,000 706,000 787,000 866,000 877,000 914,000 795,000 898,000 981,000 1,060,000 1,127,000 1,206,000 1,293,000 1,349,000 1,423,000 1,397,000 1,372,000 631,000 460,000 
        operating lease right-of-use assets
      		8,500,000 8,946,000 7,663,000 8,675,000 9,135,000 8,759,000 680,000 1,284,000 1,428,000 1,614,000 1,287,000 1,431,000 1,254,000 1,468,000 1,569,000 1,664,000 1,758,000 1,854,000 1,949,000 2,029,000 2,107,000 2,280,000 2,361,000 941,000 969,000 
        intangible assets
      		231,895,000 237,870,000 243,845,000 249,819,000 255,794,000 261,768,000 257,443,000 252,925,000 258,338,000 56,437,000 57,695,000 58,954,000 45,032,000 18,481,000 18,740,000 19,000,000          
        other assets
      		9,918,000 6,842,000 5,474,000 5,382,000 5,380,000 3,972,000 3,873,000 4,165,000 1,510,000 1,153,000 1,337,000 1,382,000 1,710,000 2,033,000 1,786,000 1,641,000 1,427,000 1,426,000 1,272,000 336,000 161,000 160,000 324,000 84,000 1,871,000 
        total assets
      		785,115,000 725,825,000 690,245,000 670,754,000 667,893,000 660,754,000 651,962,000 646,621,000 650,642,000 443,588,000 333,530,000 352,906,000 364,347,000 278,148,000 294,651,000 235,167,000 247,668,000 222,241,000 240,864,000 141,865,000 155,766,000 172,803,000 146,712,000 158,273,000 104,266,000 
        liabilities and stockholders’ equity
      		                         
        current liabilities:
      		                         
        accounts payable
      		12,167,000 17,657,000 11,639,000 14,618,000 9,545,000 9,842,000 15,983,000 7,416,000 7,369,000 14,446,000 6,440,000 8,690,000 10,548,000 4,943,000 9,166,000 5,003,000 5,380,000 5,658,000 3,151,000 5,177,000 3,024,000 3,265,000 3,351,000 2,665,000 2,348,000 
        accrued expenses and other current liabilities
      		148,192,000 127,139,000 115,938,000                       
        total current liabilities
      		160,359,000 144,796,000 127,577,000 126,551,000 115,751,000 112,308,000 105,909,000 87,064,000 74,664,000 58,203,000 48,843,000 64,729,000 51,398,000 34,553,000 42,596,000 50,387,000 29,028,000 35,022,000 18,462,000 18,792,000 16,580,000 13,548,000 13,076,000 10,909,000 11,108,000 
        operating lease liabilities, noncurrent
      		7,361,000 7,884,000 7,003,000 7,972,000 8,480,000 8,244,000 328,000 617,000 868,000 1,154,000 1,055,000 1,257,000 1,311,000 1,713,000 1,903,000 2,088,000 2,271,000 2,452,000 2,627,000 2,788,000 2,947,000 3,103,000 3,251,000 1,124,000  
        convertible notes payable, net, noncurrent
      		309,368,000 308,933,000 308,509,000 308,082,000                      
        other liabilities
      		15,981,000 9,054,000 13,900,000 2,509,000 3,972,000 3,972,000 4,287,000 3,849,000 7,000 10,000 772,000 4,532,000 4,324,000 10,000 17,000 19,000 22,000 24,000 29,000 30,000 31,000 34,000 36,000 37,000 42,000 
        total liabilities
      		493,069,000 470,667,000 456,989,000 445,114,000 435,869,000 431,766,000 417,359,000 397,951,000 381,561,000 364,978,000 192,380,000 210,869,000 195,050,000 169,216,000 174,439,000 178,771,000 151,931,000 88,358,000 68,769,000 21,610,000 19,558,000 16,685,000 16,363,000 12,070,000 12,390,000 
        commitments and contingencies
      		                         
        stockholders’ equity:
      		                         
        preferred stock, 0.0001 par value...
      		                         
        common stock, 0.0001 par value...
      		5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 4,000 4,000 4,000 4,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 2,000 2,000 1,000 
        additional paid-in capital
      		953,818,000 919,520,000 892,367,000 870,189,000 851,490,000 835,616,000 816,129,000 803,260,000 791,114,000 575,522,000 563,964,000 535,074,000 526,099,000 402,825,000 377,403,000 371,104,000 363,344,000 357,583,000 345,180,000 256,048,000 250,349,000 247,350,000 200,119,000 198,052,000 1,893,000 
        accumulated deficit
      		-661,814,000 -664,719,000 -658,858,000 -644,181,000 -620,391,000 -606,156,000 -581,518,000 -556,239,000 -520,580,000 -496,992,000 -422,954,000 -392,824,000 -356,393,000 -293,765,000 -257,159,000 -314,705,000 -267,597,000 -223,703,000 -173,171,000 -135,968,000 -114,462,000 -91,211,000 -69,901,000 -51,949,000 -36,862,000 
        accumulated other comprehensive income
      		37,000 352,000  -373,000 920,000 -477,000 -13,000 1,644,000  76,000 136,000 -217,000   -35,000 -6,000 -13,000  83,000 172,000 318,000 -24,000 129,000 98,000 28,000 
        total stockholders’ equity
      		292,046,000 255,158,000 233,256,000 225,640,000 232,024,000 228,988,000 234,603,000 248,670,000 269,081,000 78,610,000 141,150,000 142,037,000 169,297,000 108,932,000 120,212,000 56,396,000 95,737,000 133,883,000 172,095,000 120,255,000 136,208,000 156,118,000 130,349,000 146,203,000  
        total liabilities and stockholders’ equity
      		785,115,000 725,825,000 690,245,000 670,754,000 667,893,000 660,754,000 651,962,000 646,621,000 650,642,000 443,588,000 333,530,000 352,906,000 364,347,000 278,148,000 294,651,000 235,167,000 247,668,000 222,241,000 240,864,000 141,865,000 155,766,000 172,803,000    
        accumulated other comprehensive loss
      		  -258,000      -1,458,000    -413,000 -131,000            
        accrued expenses
      		   110,224,000 104,700,000 101,394,000 89,568,000 78,544,000 66,213,000 42,693,000 40,399,000 54,018,000 38,311,000 26,883,000 30,723,000 43,847,000 20,775,000 27,781,000 13,411,000 12,999,000 13,026,000 9,772,000 9,328,000 7,912,000 8,539,000 
        operating lease liabilities, current
      		   1,709,000 1,506,000 1,072,000                    
        convertible notes payable
      		    307,666,000 307,242,000 306,835,000 306,421,000 306,022,000 305,611,000                
        operating lease liabilities
      		      358,000 1,104,000 1,082,000 1,064,000 914,000 931,000 775,000 731,000 711,000 690,000 671,000 653,000 636,000 616,000 530,000 511,000 397,000 332,000 221,000 
        restricted cash equivalents
      		          100,000,000 100,000,000 100,000,000 100,000,000 100,000,000           
        derivative liability
      		          1,090,000 1,090,000 1,764,000 1,996,000 1,996,000 847,000 2,202,000 930,000 1,264,000       
        revenue interest liability
      		          141,710,000 140,351,000 138,017,000 132,940,000 129,923,000 126,277,000 120,610,000 50,860,000 47,651,000       
        other receivable
      		               400,000          
        investments
      		               14,997,000 14,990,000         
        liabilities, redeemable convertible preferred stock, redeemable common stock and stockholders’ equity
      		                         
        series a redeemable convertible preferred stock, 0.0001 par value...
      		                        119,826,000 
        redeemable common stock, 0.0001 par value...
      		                        6,990,000 
        stockholders’ equity
      		                         
        total liabilities, redeemable convertible preferred stock, redeemable common stock and stockholders’ equity
      		                      146,712,000 158,273,000  
        liabilities, redeemable convertible preferred stock, redeemable common stock and stockholders’ deficit
      		                         
        stockholders’ deficit:
      		                         
        total stockholders’ deficit
      		                        -34,940,000 
        total liabilities, redeemable convertible preferred stock, redeemable common stock and stockholders’ deficit
      		                        104,266,000 
        operating expenses:
      		                         
        research and development
      		                        11,589,000 
        general and administrative
      		                        2,445,000 
        total operating expenses
      		                        14,034,000 
        income from operations
      		                        -14,034,000 
        interest income
      		                        468,000 
        other income
      		                        9,000 
        net income
      		                        -13,557,000 
        net income per common share, basic and diluted
      		                        -5,310 
        weighted-average common shares outstanding, basic and diluted
      		                        2,551,822,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
                             
          operating activities
        		                     
          net income
        		2,905,000 -5,861,000 -14,677,000 -23,790,000 -14,235,000 -24,638,000 -25,279,000 -35,659,000 -23,588,000 -74,038,000 -30,130,000 -36,431,000 -36,606,000 57,546,000 -47,108,000 -43,894,000 -50,532,000 -37,203,000 -21,506,000 -23,251,000 -21,310,000 
          reconciliation of net income to net cash from operating activities:
        		                     
          stock-based compensation
        		18,127,000 18,468,000 15,803,000 13,251,000 11,908,000 11,835,000 11,450,000 9,720,000 8,385,000 8,357,000 8,561,000 6,896,000 6,561,000 5,564,000 7,415,000 4,823,000 5,285,000 3,579,000 3,428,000 2,974,000 2,573,000 
          depreciation and amortization
        		6,062,000 6,056,000 6,052,000 6,056,000 6,055,000 5,854,000 5,664,000 5,494,000 2,662,000 1,336,000 1,337,000 1,201,000 342,000 342,000 84,000 79,000 90,000 85,000 77,000 70,000 73,000 
          inventory reserves and firm commitment losses
        		540,000 0 2,349,000 831,000 107,000 1,439,000 237,000               
          amortization of debt discount and offering costs
        		443,000 427,000 433,000 416,000 424,000 407,000 414,000 399,000 411,000             
          unrealized foreign exchange gain
        		-643,000 -612,000 -658,000  1,007,000 -355,000 -1,734,000               
          non-cash lease expense
        		447,000 436,000 390,000 369,000 400,000   144,000 186,000             
          other
        		-345,000 -318,000 -356,000 -370,000 -450,000 -493,000 518,000               
          change in operating assets and liabilities:
        		                     
          accounts receivable
        		-3,146,000 -9,068,000 -16,833,000 -10,864,000 -8,100,000 -5,431,000 12,969,000 -20,134,000 -12,508,000 -10,665,000 -667,000 -7,657,000 -4,605,000         
          prepaid and other current assets
        		-4,632,000 -4,085,000 -3,029,000 273,000 -3,467,000 1,427,000 918,000 -153,000 -2,665,000 -742,000 -40,000      -112,000     
          inventory
        		-1,159,000 -2,335,000 -2,672,000 -214,000 3,663,000 -3,442,000 -3,173,000 -2,187,000 -439,000 -989,000 -778,000 598,000 -67,000         
          other assets
        		-2,684,000 -1,250,000 -92,000 -2,000 -1,408,000 -99,000 11,000 -691,000 -49,000 -56,000 285,000 307,000 -247,000 -145,000 -212,000 -2,000 -160,000     
          accounts payable, accrued expenses and other liabilities
        		24,346,000 10,577,000 11,737,000 9,339,000 12,752,000 6,944,000 11,277,000 12,528,000 10,286,000 24,176,000 -16,212,000 -5,000 -8,070,000 9,020,000 3,779,000 -7,372,000 17,228,000 -1,972,000 2,169,000 3,010,000 476,000 
          operating lease liabilities
        		-580,000 -395,000 -408,000 -214,000 -106,000 -193,000 -269,000 -229,000 -268,000 -224,000 -219,000 -183,000 -170,000 -164,000 -164,000 -164,000 -157,000 -141,000 -73,000 -135,000 -36,000 
          net cash from operating activities
        		39,681,000 12,040,000 -1,961,000 -5,068,000 3,984,000 -3,803,000 15,212,000 -16,618,000 -18,221,000 -2,331,000 -33,774,000 -34,270,000 -39,669,000 -33,147,000 -34,202,000 -40,199,000 -25,210,000 -36,279,000 -17,451,000 -16,994,000 -18,351,000 
          capital expenditures
        		-187,000 -126,000 -41,000 -20,000 -181,000 -779,000 -13,000 0 0 -68,000 -41,000 -242,000  -3,000 -18,000 0 -3,000 -28,000 -46,000 -53,000 -98,000 
          free cash flows
        		39,494,000 11,914,000 -2,002,000 -5,088,000 3,803,000 -4,582,000 15,199,000 -16,618,000 -18,221,000 -2,399,000 -33,815,000 -34,512,000  -33,150,000 -34,220,000 -40,199,000 -25,213,000 -36,307,000 -17,497,000 -17,047,000 -18,449,000 
          investing activities
        		                     
          purchase of investments
        		-20,860,000 -31,537,000 -33,526,000 -11,483,000 -15,605,000   0 0 -4,885,000 -22,444,000 0  -18,974,000 -49,719,000 -45,955,000 -83,381,000 -22,571,000 -37,971,000   
          proceeds from maturities of investments
        		18,820,000 25,064,000 17,433,000 12,144,000    3,000,000 30,000,000 55,500,000 64,500,000 27,000,000 36,500,000 38,000,000 47,500,000 21,500,000 48,600,000 14,500,000 9,500,000 32,400,000 29,500,000 
          purchase of property and equipment
        		-187,000 -126,000 -41,000 -20,000 -181,000 -779,000 -13,000 0 0 -68,000 -41,000 -242,000  -3,000 -18,000 0 -3,000 -28,000 -46,000 -53,000 -98,000 
          payments made for additions to intangible assets
        		   0 -10,000,000   -5,000,000 0             
          net cash from investing activities
        		-2,227,000 -6,599,000 -16,134,000 641,000 -18,036,000 -72,717,000 -13,000 -2,000,000 -182,762,000 35,547,000 42,015,000 26,758,000  108,023,000 -2,237,000 -24,455,000 -32,784,000 -4,946,000 -18,914,000 27,973,000 33,761,000 
          financing activities
        		                     
          proceeds from issuance of common stock pursuant to equity plans
        		16,096,000 8,688,000 6,359,000 5,340,000 3,863,000 7,291,000 1,205,000 2,217,000 4,766,000 2,097,000 1,390,000           
          net cash from financing activities
        		16,096,000 8,688,000 6,359,000 5,340,000 3,863,000 7,291,000 1,205,000 1,777,000 207,129,000 114,707,000 12,987,000 -329,000 18,104,000 615,000 345,000 65,912,000 6,594,000 134,508,000 2,096,000 25,000 44,659,000 
          effect of exchange rate on cash, cash equivalents and restricted cash
        		349,000 2,226,000 1,055,000                   
          net increase in cash, cash equivalents and restricted cash
        		53,899,000 16,355,000 -10,681,000                   
          cash, cash equivalents and restricted cash at beginning of period
        		0 0 222,928,000                   
          cash, cash equivalents and restricted cash at end of period
        		53,899,000 16,355,000 212,247,000 -466,000 -10,101,000                 
          supplemental disclosure of cash flow information:
        		                     
          operating cash flows paid for operating lease
        		757,000 564,000 583,000 393,000 279,000 313,000 289,000 255,000 297,000 265,000 262,000 250,000 219,000 219,000 219,000 214,000 212,000     
          cash paid for interest
        		0   6,325,000 0                 
          cash paid for income taxes
        		504,000 1,485,000 162,000 233,000 432,000 200,000 139,000               
          non-cash operating, investing and financing activities:
        		                     
          right-of-use assets obtained in exchange for lease liabilities
        		0   0 737,000                 
          decrease in rou assets and lease liabilities due to lease modification
        		0 0 649,000 0 0 0 723,000               
          stock-based compensation capitalized to inventory
        		241,000 90,000 212,000 213,000 215,000 480,000 214,000  203,000 208,000 167,000           
          conversion of convertible notes, net into shares of common stock
        		8,000 3,000 6,000                   
          accrued milestone payments classified as intangible assets
        		     0 10,000,000               
          income from termination of revenue interest purchase agreement
        		       0 0             
          non-cash interest expense related to the revenue interest liability
        		       0 0 818,000 4,242,000      3,381,000     
          deferred income taxes associated with an acquisition
        		           0          
          unrealized foreign exchange (gain) loss
        		                     
          cash paid for acquisition
        		       0              
          proceeds from issuance of common stock in private placement, net of issuance costs
        		       -159,000              
          proceeds from issuance of common stock in at-the-market offerings, net of issuance costs
        		       0 0 0 14,480,000 0          
          proceeds from issuance of common stock in public offerings, net of issuance costs
        		           -280,000 17,384,000    6,914,000     
          proceeds from issuance of convertible notes
        		                     
          payments of deferred offering costs
        		                     
          payments on revenue interest liability
        		       0 0 -192,694,000 -2,883,000 -2,026,000 -757,000         
          cash, cash equivalents and restricted cash equivalents at beginning of period
        		   0 0 0 286,326,000 0 0 0 128,003,000 0 131,340,000         
          issuance of common stock in connection with settlement of contingent milestone and indemnification holdback liabilities
        		                     
          contingent milestone and indemnification holdback liabilities for common stock issuance in exchange for acquired intangible assets
        		                     
          issuance of common stock in exchange for acquired intangible
        		                     
          deferred tax liability incurred from acquired intangible
        		           0          
          effect of exchange rate on cash, cash equivalents and restricted cash equivalents
        		    88,000 -119,000 113,000 108,000 -315,000 -114,000 188,000 85,000 -3,000         
          net increase in cash, cash equivalents and restricted cash equivalents
        		    -10,101,000 -69,348,000 16,517,000 -16,733,000 5,831,000 147,809,000 21,416,000  14,932,000         
          costs recognized on sale of acquired inventory
        		     2,357,000 2,209,000               
          increase of inventory purchases included in accounts payable and accrued liabilities
        		     -1,778,000 -1,731,000               
          cash, cash equivalents and restricted cash equivalents at end of period
        		      302,843,000 -16,733,000 5,831,000 147,809,000 149,419,000 -7,756,000 146,272,000         
          issuance of common stock in connection with settlement of contingent milestone liability
        		                     
          deferred offering costs in accrued liabilities
        		          240,000           
          net accretion of discounts on investments
        		       -29,000 -234,000 -633,000 -829,000 -1,017,000        45,000 -52,000 
          change in fair value of derivative liability
        		           -674,000  1,149,000 -1,355,000 1,272,000 -334,000     
          change in fair value of contingent liabilities associated with acquisition
        		          532,000 226,000          
          inventory reserves and firm purchase commitment losses
        		                     
          unrealized foreign exchange loss
        		                     
          gain on sale of priority review voucher
        		                     
          proceeds from paydown of investments
        		                2,000,000     
          proceeds from sale of priority review voucher
        		                     
          proceeds from the issuance of convertible notes
        		       0 0             
          proceeds from revenue interest liability, net of issuance costs
        		             1,000 0       
          inventory purchases included in accrued liabilities
        		       3,584,000 1,025,000 1,364,000 103,000 -882,000          
          right-of-use assets obtained in exchange for lease liability
        		       0 0             
          stock-based compensation capitalized into inventory
        		                     
          issuance of common stock in exchange for acquired intangible assets
        		           0          
          contingent milestone liability for common stock issuance for acquired intangible assets
        		           0          
          indemnification holdback liability for common stock issuance in exchange for acquired intangible assets
        		           0          
          change in fair value of contingent liabilities associated with an acquisition
        		        4,000             
          inventory reserves
        		        826,000             
          commercial milestone included in accrued liabilities
        		                     
          private placement issuance costs included in accounts payable and accrued liabilities
        		                     
          reclassification of contingent milestone liability to equity in connection with issuance of common stock upon achievement of contingent milestone
        		        0 0 4,292,000           
          issuance of common stock in connection with settlement of indemnification holdback liability
        		        0             
          transaction costs from public offering included in accrued liabilities
        		                     
          indemnification holdback liability in exchange for acquired intangible assets
        		                     
          transaction costs from acquisition in accrued liabilities
        		                     
          amortization of operating lease right-of-use assets
        		          144,000 128,000 101,000 95,000 94,000 96,000 95,000 80,000 78,000 77,000 83,000 
          additions to intangible assets
        		                     
          net decrease in cash, cash equivalents and restricted cash equivalents
        		                     
          non-cash interest expense related to revenue interest liability
        		            3,774,000         
          prepaid expenses and other current assets
        		            -637,000  -2,344,000    -1,663,000 122,000 -158,000 
          proceeds from issuance of common stock pursuant to equity award plans
        		            1,477,000 735,000 345,000 938,000 80,000 732,000 27,000   
          net amortization of discounts on investments
        		            -45,000 -57,000        
          net cash from provided by investing activities
        		            36,500,000         
          payments of issuance costs related to revenue interest liability
        		                     
          operating lease right-of-use assets
        		                 0 0   
          payment of deferred offering costs in connection with the shelf registration and sales agreement
        		                 17,000    
          inventory purchases in accrued liabilities
        		                     
          noncash investing and financing activities:
        		                     
          revenue interest liability issuance costs included in accrued liabilities
        		                     
          deferred offering costs included in accrued liabilities
        		                     
          compound derivative liability related to revenue interest liability
        		                     
          non-cash interest expense on revenue interest purchase agreement
        		              5,667,000       
          proceeds from paydowns of investments
        		              0    9,603,000 9,646,000 4,359,000 
          proceeds from issuance of common stock in public offering, net of issuance costs
        		              0    2,244,000 0 44,659,000 
          effect of exchange rate on cash and cash equivalents
        		              0 3,000 -9,000 25,000 5,000 3,000 -4,000 
          net increase in cash and cash equivalents
        		              -36,094,000 1,261,000 -51,409,000 93,308,000 -34,264,000 11,007,000 60,065,000 
          cash and cash equivalents at beginning of period
        		              0 0 142,086,000 0 0 0 11,970,000 
          cash and cash equivalents at end of period
        		              -36,094,000 1,261,000 90,677,000 93,308,000 -34,264,000 11,007,000 72,035,000 
          property and equipment purchases included in accounts payable
        		                     
          net amortization (accretion) on investments
        		                6,000 40,000    
          payment of issuance costs related to the revenue interest liability
        		                -400,000     
          proceeds from the issuance of series a redeemable convertible preferred stock, net of issuance costs
        		                     
          operating lease right-of-use asset obtained in exchange for operating lease liability
        		                     
          landlord paid tenant improvements
        		                     
          conversion of series a redeemable convertible preferred stock into common stock on initial public offering
        		                     
          reclassification of redeemable common stock into common stock on initial public offering
        		                     
          proceeds from issuance of common stock in initial public offering, net of issuance costs
        		                     
          proceeds from issuance of preferred stock, net of issuance costs
        		                     
          payment of deferred offering costs
        		                     
          deferred initial public offering costs in accounts payable
        		                     
          amortization of premium on investments
        		                     
          proceeds from the issuance of preferred stock
        		                     
          net decrease in cash and cash equivalents
        		                     
          deferred initial public offering costs in accounts payable and accrued expenses
        		                     
          interest expense on convertible note
        		                     
          in process research and development
        		                     
          research and development asset acquisition
        		                     
          proceeds from convertible note, related party
        		                     
          proceeds from the sale of common stock
        		                     
          deferred public offering costs included in accrued liabilities
        		                     
          common stock issued in connection with asset acquisition
        		                     
          conversion of convertible note to preferred stock